Onconova Logo BLUE.jpg
Onconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference
22 sept. 2022 08h00 HE | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Logo BLUE.jpg
Onconova Therapeutics Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022
12 sept. 2022 08h00 HE | Onconova Therapeutics, Inc.
Data show an early signal of efficacy in an extensively pre-treated population with 1 complete response and 2 partial responses achieved in 14 evaluable patientsResponses achieved in patients with 3...
BioNTech präsentiert
BioNTech präsentiert auf ESMO-Kongress weitere ermutigende Daten aus Phase-1/2-Studie mit CAR-T-Programm BNT211 in schwer zu behandelnden soliden Tumoren
09 sept. 2022 10h30 HE | BioNTech SE
Follow-up-Daten zeigen ermutigende Anzeichen für eine klinische Anti-Tumor-Aktivität sowie ein kontrollierbares Sicherheits- und Verträglichkeitsprofil; Daten bauen auf den positiven...
BioNTech Presents En
BioNTech Presents Encouraging Phase 1/2 Follow-up Data for CAR-T Candidate BNT211 in Hard-To-Treat Solid Tumors at ESMO
09 sept. 2022 10h30 HE | BioNTech SE
Follow-up data further demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety and tolerability profile, building on the positive interim data presented at AACR in...
ITM_Logo_Claim_RGB_high-res.png
ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022
06 sept. 2022 05h00 HE | ITM Isotope Technologies Munich SE
Garching / Munich, September 6, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that a scientific poster on the design of its second...